Abstract: This retrospective cohort study explores the use of Bruton tyrosine kinase inhibitors (BTKi) in veterans with chronic lymphocytic leukaemia (CLL) and severe renal …
Abstract: Chronic lymphocytic leukemia (CLL) is a prevalent but incurable malignancy with a variable disease course. As the most common lymphoid malignancy in the United States, …
Abstract: BACKGROUND: Ibrutinib has been a first-line treatment for chronic lymphocytic leukemia since 2014. Case reports of hepatitis B virus (HBV) reactivation after ibrutinib …
Abstract: INTRODUCTION: U.S. veterans in the Veterans Affairs (VA) Healthcare System are managed in a national single-payer system with access to FDA-approved therapies. …
Abstract: Purpose: Ibrutinib is a tyrosine kinase inhibitor that is increasingly prescribed in chronic lymphocytic leukemia (CLL). Invasive fungal infections (IFIs) have been …